Pfizer (PFE) Tops Q3 EPS by 44c, Beats on Revenue; Offers FY24 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Pfizer (PFE) PT Raised to $33 at Goldman Sachs
October 30, 2024 6:16 AM EDTGoldman Sachs analyst Chris Shibutani raised the price target on Pfizer (NYSE: PFE) to $33.00 (from $32.00) while maintaining a Buy rating.
The analyst comments "Despite an impressive headline beat and raise, PFE shares underperformed on the day (-1.4% vs. -0.3% XLV). The 3Q beat was... More
